Baker holds an M.B.A. from the University of Chicago and a B.S. from the United States Military Academy at West Point.
This is an exciting time for all of us here at Pulmonx, commented Mike Baker, president and CEO of Pulmonx. With the completion of the acquisition of Emphasys Medical, Inc. and 510K clearance of our Chartis System, Pulmonx is poised to become a leader in the treatment of pulmonary disorders such as severe emphysema. These new technologies have the potential to cost-effectively improve the health of literally millions of patients globally and I’m extremely enthusiastic about the opportunity to lead this outstanding team as we work to commercialize these breakthrough products and build a strong franchise in Interventional Pulmonology.
We are very excited that Mike will be leading our company as we begin to commercialize our proprietary medical device therapies for these important indications, said Dr. Rodney Perkins, founder and chairman of the board. The strategic and leadership skills he has developed over the course of his career will be of great value to Pulmonx.
Pulmonx is a developer and marketer of minimally-invasive medical devices and technologies for the diagnosis and treatment of pulmonary disorders.
